To see if BXDC2 could modulate the cytotoxic effects of other chemotherapeutic drugs used for the treatment of bladder cancer, the cell viability in the presence of various concentrations of MTX, VBL, DOX, or GEN was compared in the control-shRNA vs. BXDC2-shRNA sublines. This evidence concerns the gene BRIX1 and urinary bladder cancer.